Next-Generation Bispecific Nanobody Targeting ALB and IgE for Food Allergy Management

VHH-P760 is a novel bispecific, humanized nanobody designed to target both albumin (ALB) and immunoglobulin E (IgE), two key molecules involved in the pathophysiology of food allergy. This candidate is currently at the biological testing stage, demonstrating substantial promise for therapeutic intervention in food allergy. By engaging albumin (ALB) and immunoglobulin E (IgE), VHH-P760 aims to offer a differentiated approach to immune modulation and sustained therapeutic effect. The molecule leverages the unique properties of nanobody-based constructs for enhanced tissue penetration and bioavailability, potentially leading to improved outcomes for individuals affected by food allergies.

Licensing Opportunity

VHH-P760 is actively available for licensing and partnership discussions. We invite collaborative engagement from pharmaceutical companies and investors seeking innovative bispecific antibody therapeutics for allergic diseases.

Development Phase

Modality

VHH-P760 represents an advanced bispecific antibody modality, engineered by fusing an anti-ALB nanobody with a terminal alanine residue to an anti-IgE nanobody incorporating the E1D mutation through a flexible 9GS linker. The single-domain nanobody structure, with its relatively small molecular size and robust folding properties, confers exceptional stability and solubility. Expression in Pichia pastoris X-33 facilitates high-yield and scalable biomanufacturing. These structural advantages of nanobodies enable superior tissue penetration, extended circulatory half-life, and increased resistance to harsh physiological conditions, which are particularly beneficial in the context of food allergy where rapid immune modulation and prolonged activity are desired.

Target

ALB and IgE are critical molecular targets with distinct yet complementary roles in immunity and disease. ALB is a highly abundant plasma protein primarily produced in the liver, playing major roles in transport and maintaining osmotic balance throughout the body. IgE is an immunoglobulin predominantly expressed by plasma cells and functions centrally in mediating allergic responses, especially in food allergy. Overactivation of IgE, binding to its receptors on mast cells and basophils, triggers hypersensitivity reactions seen in food allergy. The dual targeting of ALB and IgE provides a strategic advantage: ALB can be leveraged to extend serum half-life and improve biodistribution of biotherapeutics, while IgE engagement directly modulates the pathogenic allergic cascade. VHH-P760, by addressing both ALB and IgE, maximizes therapeutic impact and is positioned as a strategically attractive bispecific approach for food allergy intervention.

Mechanism of Action

VHH-P760 employs a dual-action mechanism by simultaneously binding to ALB and IgE. The anti-ALB moiety utilizes ALB’s abundance in serum to facilitate prolonged circulatory residence, thereby optimizing the pharmacokinetic profile and tissue distribution of the bispecific nanobody. The anti-IgE component specifically targets and neutralizes free IgE, disrupting its interaction with effector cells and blocking the initiation of the allergic cascade. This dual targeting approach results in enhanced suppression of allergic responses associated with food allergy. Beyond its current construct, the modular nanobody platform underlying VHH-P760 sets the stage for future engineering as antibody-drug conjugates (ADCs) or additional bispecific and multispecific agents, thus broadening the spectrum of potential therapeutic applications.

Food Allergy

Food allergy is a serious and increasingly prevalent immunological disorder characterized by abnormal immune responses to specific food proteins. It often presents in childhood but can emerge at any age and affects individuals worldwide. The severity ranges from mild symptoms to life-threatening anaphylaxis. Current standard therapies primarily involve strict allergen avoidance and symptomatic management with antihistamines or epinephrine auto-injectors as rescue treatments. Emerging options include immunomodulatory or desensitization therapies; however, these approaches have variable efficacy and safety profiles. Major limitations of existing treatments include lack of curative options, need for continuous vigilance, and the burden of acute interventions. There remains a substantial unmet need for innovative therapeutics that offer both immediate and durable protection with favorable safety and convenience profiles. VHH-P760, with its targeted engagement of ALB and IgE, holds significant promise to address these gaps and improve disease control and quality of life for patients with food allergy.